PerspectiveCancer Biomarkers

Visualizing the Landscape of Selection Biomarkers in Current Phase III Oncology Clinical Trials

See allHide authors and affiliations

Science Translational Medicine  02 Jun 2010:
Vol. 2, Issue 34, pp. 34ps27
DOI: 10.1126/scitranslmed.3001087

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Selection biomarkers are disease-associated analytes whose measurement is either an essential step in patient screening or the primary objective of a clinical trial. The public database contains information on most active phase III oncology clinical trials that can be examined for trends in the development of cancer therapies. But for selection biomarkers, such information is not easily accessible and so has not been examined in a comprehensive way. Here we provide a global analysis of selection biomarkers currently in use in the oncology phase III trial arena.


  • Citation: R. Sikorski, B. Yao, Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials. Sci. Transl. Med. 2, 34ps27 (2010).

View Full Text

Stay Connected to Science Translational Medicine